VIGL Stock Price, Vigil Neuroscience, Inc. Quote, Chart

Market Summary

USD3.52-0.02

Delayedas of 17 May 2024, 10:05 am

-0.56%

VIGL Stock Price

View Fullscreen

VIGL RSI Chart

VIGL Valuation

Market Cap

133.0M

Price/Earnings (Trailing)

-1.61

Price/Free Cashflow

-1.88

VIGL Price/Earnings (Trailing)

VIGL Profitability

Return on Equity

-79.77%

Return on Assets

-66.19%

Free Cashflow Yield

-53.16%

VIGL Fundamentals

VIGL Earnings

Earnings (TTM)

-82.8M

Earnings Growth (Yr)

-0.73%

Earnings Growth (Qtr)

10.07%

Breaking Down VIGL Revenue

52 Week Range

3.4411.11

(Low)(High)

Last 7 days

7.6%

Last 30 days

16.8%

Last 90 days

16.8%

Trailing 12 Months

-58.3%

How does VIGL drawdown profile look like?

VIGL Financial Health

Current Ratio

12.38

VIGL Investor Care

Shares Dilution (1Y)

5.32%

Diluted EPS (TTM)

-2.12

Tracking the Latest Insider Buys and Sells of Vigil Neuroscience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 20, 2023	magovcevic-liebisch ivana	bought	15,000	3.75	4,000	president and ceo
Nov 18, 2022	papapetropoulos spyros	acquired	567	1.89	300	chief medical officer
Nov 18, 2022	papapetropoulos spyros	sold	-4,200	14.00	-300	chief medical officer
May 17, 2022	thorp clay	bought	44,189	2.9671	14,893	-
May 16, 2022	thorp clay	bought	60,221	2.7622	21,802	-
May 05, 2022	thackaberry evan	bought	6,000	4.00	1,500	svp, head of early development
May 03, 2022	magovcevic-liebisch ivana	bought	3,940	3.9402	1,000	president and ceo
May 03, 2022	verni christopher	bought	15,074	3.7686	4,000	general counsel
May 03, 2022	papapetropoulos spyros	bought	13,591	3.3978	4,000	chief medical officer
May 03, 2022	ziolkowski jennifer lynn	bought	15,097	3.7744	4,000	chief financial officer

Which funds bought or sold VIGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	added	223	4,092,010	5,900,710	0.83%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	82,181	82,181	-%
May 15, 2024	683 Capital Management, LLC	new	-	3,392,610	3,392,610	0.25%
May 15, 2024	DAFNA Capital Management LLC	unchanged	-	2,154	244,889	0.06%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	69,486	69,486	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	112,970	112,970	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	186	100,282	153,443	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-56.41	-251,761	197,657	-%
May 15, 2024	BVF INC/IL	unchanged	-	54,409	6,184,490	0.17%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	13,466	1,530,720	0.03%

Are Funds Buying or Selling VIGL?

Are funds buying VIGL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VIGL

No. of Funds

Unveiling Vigil Neuroscience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	artal international s.c.a.	4.9%	1,811,191	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.0%	6	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.62%	3,649,726	SC 13G/A
Feb 12, 2024	flynn james e	3.27%	1,173,523	SC 13G/A
Feb 09, 2024	artal international s.c.a.	5.0%	1,811,191	SC 13G/A
Feb 14, 2023	citadel advisors llc	6.1%	6	SC 13G/A
Feb 14, 2023	hatteras venture partners vi, lp	4.4%	1,562,578	SC 13G
Feb 13, 2023	artal international s.c.a.	6.3%	2,243,352	SC 13G/A
Feb 10, 2023	flynn james e	5.77%	2,052,010	SC 13G/A
Feb 10, 2023	vida ventures gp iii, l.l.c.	14.1%	5,015,929	SC 13D

Recent SEC filings of Vigil Neuroscience, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading

Peers (Alternatives to Vigil Neuroscience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Vigil Neuroscience, Inc. News

Latest updates

Vigil Neuroscience, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-11.2%	125	141	159	175	192	200	216	158	173	102
Current Assets	-12.6%	107	122	140	156	172	198	213	156	170	97.00
Cash Equivalents	1.3%	53.00	52.00	57.00	59.00	96.00	187	204	149	163	92.00
Net PPE	-6.2%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00
Liabilities	-13.5%	21.00	25.00	23.00	22.00	21.00	11.00	10.00	7.00	7.00	10.00
Current Liabilities	-26.2%	9.00	12.00	10.00	8.00	7.00	11.00	10.00	7.00	7.00	10.00
Shareholder's Equity	-10.7%	104	116	136	154	171	189	206	151	166	-69.44
Retained Earnings	-9.0%	-242	-222	-200	-180	-159	-140	-121	-104	-87.20	-71.83
Additional Paid-In Capital	2.2%	347	339	336	334	331	329	328	255	253	2.00
Shares Outstanding	4.7%	38.00	36.00	36.00	36.00	36.00	36.00	29.00	28.00	28.00	2.00
Float	-	-	-	-	233	-	-	-	30.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-41.1%	-21,881	-15,510	-17,314	-15,353	-22,186	-17,087	-15,925	-13,993	-18,144	-17,347	-11,073	-6,164	-4,763
Share Based Compensation	-7.0%	2,312	2,486	2,426	2,257	1,734	1,501	1,494	1,461	1,021	762	556	434	333
Cashflow From Investing	54.5%	16,466	10,655	15,314	-22,103	-69,004	-272	-416	-91.00	-142	-	-	-	-
Cashflow From Financing	9681.1%	5,184	53.00	53.00	579	203	101	71,292	-328	90,190	-1,862	89,704	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VIGL Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Operating expenses:

Research and development

^[1]

$ 14,326

$ 13,834

General and administrative

7,089

6,941

Total operating expenses

21,415

20,775

Loss from operations

(21,415)

(20,775)

Other income (expense):

Interest income, net

1,477

985

Other income (expense), net

(2)

(5)

Total other income, net

1,475

980

Net loss

$ (19,940)

$ (19,795)

Net loss per share attributable to common stockholders, basic

$ (0.5)

$ (0.51)

Net loss per share attributable to common stockholders, diluted

$ (0.5)

$ (0.51)

Weighted-average common shares outstanding, basic

39,864,111

38,546,012

Weighted-average common shares outstanding, diluted

39,864,111

38,546,012

Comprehensive loss:

Net loss

$ (19,940)

$ (19,795)

Unrealized gain (loss) on available for sale securities

(25)

106

Total comprehensive loss

$ (19,965)

$ (19,689)

[1]	Includes related party amounts of $0 for the three months ended March 31, 2024, and $43 for the three months ended March 31, 2023 (see Note 10).

VIGL Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 51,761	$ 51,992
Marketable securities	49,884	65,948
Prepaid expenses and other current assets	4,898	3,967
Total current assets	106,543	121,907
Property and equipment, net	1,637	1,745
Operating lease right-of-use assets	15,801	16,147
Financing lease right-of-use assets	44	49
Restricted cash	927	927
Other assets	126	83
Total assets	125,078	140,858
Current liabilities:
Accounts payable	1,491	1,946
Accrued expenses and other current liabilities	6,175	8,810
Operating lease liabilities	937	905
Total current liabilities	8,603	11,661
Operating lease liabilities, net of current portion	12,693	12,945
Total liabilities	21,296	24,606
Commitments and contingencies (Note 11)
Stockholders' equity:
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 0 share issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 37,628,635 shares issued as of March 31, 2024 and 35,929,035 shares issued as of December 31, 2023; and 37,584,312 shares outstanding as of March 31, 2024 and 35,884,712 shares outstanding as of December 31, 2023	4	4
Additional paid-in capital	346,520	339,025
Accumulated other comprehensive income	(30)	(5)
Accumulated deficit	(242,712)	(222,772)
Total stockholders' equity	103,782	116,252
Total liabilities and stockholders' equity	$ 125,078	$ 140,858

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
WEBSITE	vigilneuro.com
INDUSTRY	Biotechnology
EMPLOYEES	61

Vigil Neuroscience, Inc. Frequently Asked Questions

What is the ticker symbol for Vigil Neuroscience, Inc.? What does VIGL stand for in stocks?

VIGL is the stock ticker symbol of Vigil Neuroscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vigil Neuroscience, Inc. (VIGL)?

As of Thu May 16 2024, market cap of Vigil Neuroscience, Inc. is 133.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers. The fair value of Vigil Neuroscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vigil Neuroscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vigil Neuroscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether VIGL is over valued or under valued. Whether Vigil Neuroscience, Inc. is cheap or expensive depends on the assumptions which impact Vigil Neuroscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIGL.